Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis
Fumaric acid esters (FAEs) have been used in the treatment of psoriasis in some European countries for over 20 years, and are recommended in the European guidelines for the management of moderate to severe plaque psoriasis. Dimethyl fumarate (Skilarence®; hereafter referred to as DMF) is an orally administered FAE indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy; unlike other available FAEs, it is not formulated in combination with monoethyl fumarate salts. EU approval was based on results of the phase III BRIDGE trial, and supported by previous publications of FAE preparations, including a combination of FAEs containing dimethyl fumarate and monoethyl fumarate salts (DMF/MEF; Fumaderm®). In the BRIDGE trial, DMF was superior to placebo in terms of the proportion of patients achieving a ≥ 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) and a Physician Global Assessment score of 0 (clear) or 1 (almost clear) at week 16. DMF was also noninferior to DMF/MEF for PASI 75 at week 16. Patients receiving DMF also reported clinically meaningful improvements in body surface area involvement and health-related quality of life. The safety profile of DMF was similar to that of DMF/MEF, and no major or unexpected safety concerns were identified. The most common adverse events (flushing and gastrointestinal disorders) occurred mainly during the first few weeks of treatment. Currently available data indicate that DMF is an effective oral systemic treatment option for patients with moderate to severe plaque psoriasis.
During the peer review process, the manufacturer of DMF was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/D15CF06028AE6C06.
- 2.World Health Organization. Global report on psoriasis. 2016. http://www.who.int. Accessed 8 Dec 2017.
- 3.Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74.CrossRefPubMedGoogle Scholar
- 5.Okpara E. Dimethyl fumarate for moderate to severe chronic plaque psoriasis. Newcastle: Regional Drug & Therapeutics Centre; 2017.Google Scholar
- 7.European Medicines Agency. Summary of product characteristics: Skilarence 30 mg gastro-resistant tablets, Skilarence 120 mg gastro-resistant tablets. 2017. http://www.ema.europa.eu. Accessed 8 Dec 2017.
- 8.European Medicines Agency. Assessment report: Skilarence. 2017. http://www.ema.europa.eu. Accessed 8 Dec 2017.
- 13.Bovenschen HJ, Langewouters AM, van de Kerkhof PC. Dimethylfumarate for psoriasis: pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am J Clin Dermatol. 2010;11(5):343–50.CrossRefPubMedGoogle Scholar
- 19.Mrowietz U, Szepietowski J, Loewe R, et al. Clinical efficacy of LAS41008 (dimethyl fumarate) in pre-treated vs naive patients with moderate-to-severe chronic plaque psoriasis: post-hoc analysis of the BRIDGE study [abstract no. P1848 plus poster]. In: European Academy of Dermatology and Venerology. 2017.Google Scholar
- 20.Mrowietz U, Szepietowski J, Loewe R, et al. LAS41008 (dimethyl fumarate) for psoriasis: analysis of the efficacy of treatment according to severity of disease at baseline [abstract no. P1846 plus poster]. In: European Academy of Dermatology and Venereology. 2017.Google Scholar
- 21.Van de Kerkhof P, Szepietowski JC, Loewe R, et al. Treatment with LAS41008 (dimethyl fumarate) improves health-related quality of life and has a positive impact on the patient benefit index in adults with moderate-to-severe chronic plaque psoriasis: results of the BRIDGE study [abstract P1998 plus poster]. In: European Academy of Dermatology and Venerology. 2016.Google Scholar
- 42.Zweegers J, de Jong EM, Nijsten TE, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J. 2014;20(3).Google Scholar
- 45.Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024–32.CrossRefPubMedGoogle Scholar